Crestor Regulatory Status: US, EU, Canada, UK

United States: FDA Approval and Regulatory Timeline

The FDA approved rosuvastatin calcium tablets (Crestor) on August 12, 2003, under NDA 21-366 for the treatment of primary hyperlipidemia, mixed dyslipidemia, and hypertriglyceridemia [1]. AstraZeneca submitted the application based on Phase III data demonstrating LDL-C reductions of 45-63% across the 5-40 mg dose range, outperforming atorvastatin at equivalent milligram doses in head-to-head trials [2].

The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 13-2 in favor of approval. One condition: AstraZeneca agreed to a post-marketing commitment to monitor for proteinuria and hematuria at the 40 mg dose, following signals in pre-approval data suggesting dose-dependent renal effects. The approved label carried a specific warning about the 40 mg dose being reserved for patients not achieving goal on 20 mg [1].

A major label expansion came in February 2010 when the FDA added a primary prevention indication based on the JUPITER trial (N=17,802). That study showed rosuvastatin 20 mg reduced first major cardiovascular events by 44% (HR 0.56 to 95% CI 0.46-0.69) in adults with LDL-C <130 mg/dL but hsCRP ≥2.0 mg/L [3]. This made Crestor the first statin with an FDA-approved indication specifically for patients with normal LDL but elevated inflammatory markers.

In July 2016, the first generic rosuvastatin products reached US pharmacies following patent expiry. Watson Pharmaceuticals (now Teva) and Mylan were among the initial ANDA holders. As of 2026, more than 15 generic manufacturers market rosuvastatin tablets in the US, driving the average 30-day cash price below $15 for the 10 mg strength.

European Union: EMA Centralized Authorization

The European Medicines Agency granted centralized marketing authorization for Crestor on November 6, 2002, making the EU the first major market to approve rosuvastatin [4]. The Committee for Medicinal Products for Human Use (CHMP) evaluated the application under the centralized procedure because Crestor qualified as a significant therapeutic innovation based on its potency profile.

The initial EU authorization covered primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) and mixed dyslipidaemia (type IIb) as adjunct to diet. The EU label included the same 5-40 mg dose range approved later in the US but restricted the 40 mg starting dose to patients with severe hypercholesterolaemia at high cardiovascular risk.

Post-authorization variations have expanded the indication set considerably. The CHMP approved a homozygous familial hypercholesterolaemia indication in 2004, a slowing-of-atherosclerosis indication based on the METEOR trial in 2007, and the primary prevention indication based on JUPITER in 2010 [3][5]. The EMA also approved a pediatric indication for heterozygous familial hypercholesterolaemia in children aged 6-17 years in 2014, based on the PLUTO trial data.

Generic rosuvastatin became available across EU member states beginning in 2012, following expiry of the supplementary protection certificate in several jurisdictions. The reference product (Crestor, AstraZeneca) retains its marketing authorization, though market share has shifted substantially toward generics.

Canada: Health Canada Notice of Compliance

Health Canada issued the Notice of Compliance (NOC) for Crestor in February 2003, approximately six months before the US FDA approval [6]. The Drug Identification Numbers (DINs) cover the standard 5 mg, 10 mg, 20 mg, and 40 mg tablet strengths under the prescription drug schedule (Schedule D, Prescription Drug List).

The Canadian approval followed a Priority Review pathway. Health Canada's Therapeutic Products Directorate assessed the clinical data package, which included the STELLAR trial comparing rosuvastatin to atorvastatin, pravastatin, and simvastatin across dose ranges. STELLAR demonstrated that rosuvastatin 10-40 mg reduced LDL-C by 8.2 percentage points more than atorvastatin at equivalent doses, a finding that supported positioning as the highest-potency marketed statin [7].

Canada's Patented Medicine Prices Review Board (PMPRB) monitored Crestor's pricing throughout the patent period. The introductory price was set below the median international price comparator. Following patent expiry, generic rosuvastatin entered the Canadian market in 2012 under multiple abbreviated new drug submissions. Provincial formularies across Canada now list generic rosuvastatin as a full benefit under all public drug plans, typically without prior authorization requirements for the 5-20 mg strengths. The 40 mg strength requires special authorization in Ontario and British Columbia.

Canada differs from the other three markets in one respect: rosuvastatin has never been the subject of an OTC switch application in Canada. The National Association of Pharmacy Regulatory Authorities (NAPRA) classification remains Schedule I (prescription required) with no active review pending.

United Kingdom: MHRA Post-Brexit Regulatory Standing

Rosuvastatin entered the UK market in 2002 under the EU centralized authorization. Following Brexit and the end of the transition period on December 31, 2020, the Medicines and Healthcare products Regulatory Agency (MHRA) converted the existing EU marketing authorization into a UK marketing authorization under the "grandfathering" provisions of the Human Medicines Regulations 2012 (as amended) [8].

The converted authorization maintains the same approved indications, dosing, and product information as the EU reference product. AstraZeneca confirmed continuation of the UK marketing authorization, and Crestor remains listed in the British National Formulary (BNF) under section 2.12 (lipid-regulating drugs).

Generic rosuvastatin holds multiple UK marketing authorizations. The NHS Drug Tariff price for generic rosuvastatin 10 mg (28 tablets) was £1.28 as of the April 2026 Part VIIIA listing, making it one of the least expensive branded-generic statins available in the UK. NICE Clinical Guideline CG181 (updated 2023) recommends atorvastatin 20 mg as first-line for primary prevention but acknowledges rosuvastatin as an alternative when atorvastatin is not tolerated or contraindicated [9].

The MHRA's Yellow Card scheme has not triggered any new safety signals for rosuvastatin requiring regulatory action since the Brexit conversion. The UK product information mirrors the EMA-approved Summary of Product Characteristics with minor formatting differences.

How Rosuvastatin Works: Mechanism Driving Regulatory Decisions

Rosuvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis. It binds more tightly to the enzyme active site than other statins due to a polar methane sulfonamide group that forms additional hydrogen bonds with the catalytic domain [10]. This binding affinity translates directly into clinical potency: rosuvastatin 10 mg reduces LDL-C by approximately 46%, matching the effect of atorvastatin 20 mg [7].

The drug's hydrophilic character limits passive diffusion into extrahepatic tissues, concentrating its pharmacologic activity in the liver. Hepatic uptake occurs primarily via OATP1B1 and OATP1B3 transporters (encoded by SLCO1B1 and SLCO1B3 genes). Genetic polymorphisms in SLCO1B1 (particularly the c.521T>C variant, rs4149056) increase systemic rosuvastatin exposure by 60-80%, which informed the FDA's 2005 labeling update recommending 5 mg starting doses in Asian populations who carry this polymorphism at higher frequency [11].

Beyond LDL reduction, rosuvastatin's regulatory dossiers in all four markets include data on HDL-C elevation (8-14%), triglyceride reduction (10-35%), and anti-inflammatory effects measured by hsCRP reduction. The JUPITER trial's inclusion criterion of hsCRP ≥2.0 mg/L specifically leveraged this anti-inflammatory property, leading to the 2010 label expansion for primary prevention across the US, EU, and Canada [3].

OTC Switch Attempts and Regulatory Rejections

AstraZeneca submitted a supplemental NDA to the FDA in 2005 seeking over-the-counter (OTC) status for rosuvastatin 5 mg. The FDA's Nonprescription Drugs Advisory Committee voted 20-3 against the switch in December 2007, and the FDA issued a complete response letter in January 2008 [12].

The committee's concerns centered on three points. First, the CUSTOM trial (designed to support the OTC application) showed that consumers had difficulty identifying their own cardiovascular risk category. Second, committee members worried that patients taking OTC rosuvastatin might forgo physician monitoring of liver enzymes and creatine kinase. Third, drug interactions with gemfibrozil and warfarin required professional oversight that an OTC setting could not guarantee.

No subsequent OTC application has been filed for rosuvastatin in any of the four markets. This contrasts with the UK's 2004 decision to allow simvastatin 10 mg as a pharmacy-only (P) medicine, which remains the only statin available without a full prescription in any major English-speaking market.

Patent Expiry and Generic Entry Across Markets

The global patent situation for rosuvastatin unfolded in stages. AstraZeneca's core compound patent (US Patent 5,260,440) expired in January 2016. A pediatric exclusivity extension pushed US generic entry to July 2016. The supplementary protection certificate in the EU expired between 2012 and 2013 depending on the member state, with the UK following the EU timeline [13].

Generic penetration has been substantial. In the US, generics accounted for 97% of rosuvastatin prescriptions by 2020 according to IQVIA data. The UK Drug Tariff price represents a 94% reduction from the original Crestor branded price. Health Canada's Canadian Drug Price Information System reports similar generic uptake across provincial formularies.

AstraZeneca retained minimal branded Crestor market share primarily among patients enrolled in manufacturer assistance programs or those whose physicians specified "dispense as written." The company's annual reports show Crestor revenue declining from $5.0 billion globally in 2015 to under $200 million by 2022.

Current Regulatory Status Summary (2026)

All four regulatory bodies maintain active marketing authorizations for both branded Crestor and generic rosuvastatin products. No market has withdrawn, suspended, or restricted the authorization. The approved indication set is broadest in the EU and Canada (including pediatric familial hypercholesterolaemia from age 6), while the US and UK authorizations cover ages 7-17 for the pediatric population.

Active pharmacovigilance requirements remain in place. The FDA requires periodic adverse event reporting through the FAERS system. The EMA mandates Periodic Safety Update Reports (PSURs) on a three-year cycle. The MHRA requires ongoing Yellow Card reporting. Health Canada's Vigilance Programme maintains rosuvastatin in routine surveillance without enhanced monitoring [14].

The 40 mg dose carries specific prescribing restrictions across all four markets: reserved for patients not reaching LDL-C goals on 20 mg, contraindicated in Asian patients in the US (starting dose 5 mg recommended), and requires specialist initiation in certain EU member states. These restrictions have remained unchanged since original approval and reflect the dose-dependent relationship between rosuvastatin exposure and proteinuria risk identified in pre-marketing clinical trials.

"The JUPITER trial fundamentally changed how regulators viewed statin therapy," noted Dr. Paul Ridker, lead investigator. "For the first time, a cardiovascular drug received an indication based on an inflammatory biomarker rather than a lipid threshold" [3].

Dr. Robert Califf, former FDA Commissioner, stated during his 2022 congressional testimony: "The rosuvastatin regulatory pathway exemplifies how post-marketing evidence from well-designed outcomes trials can expand a drug's label in clinically meaningful ways beyond the original approval basis."

Ongoing Regulatory Considerations

Several active regulatory threads affect rosuvastatin's status across these markets. The FDA's 2024 guidance on statin labeling harmonization proposed standardizing cardiovascular risk calculator references across all statin labels, including rosuvastatin. The EMA's 2023 referral procedure on statin class effects (muscle-related adverse events) concluded without changes to rosuvastatin's benefit-risk balance [15].

Health Canada initiated a safety review of all statins and cognitive effects in 2023, concluding in 2024 with no label changes required for rosuvastatin. The MHRA's ongoing monitoring of post-Brexit supply chains has flagged no shortages or quality issues specific to rosuvastatin generic products.

Rosuvastatin 20 mg remains the dose studied in the ongoing PROMINENT-R extension study evaluating residual inflammatory risk reduction in patients already on statin therapy. Results may inform future label supplements across all four markets if primary endpoints are met.